Tech Transfer Deals, February 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced December 2014 through January 2015.

More from Deals

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

More from Business

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By 

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By 

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.